Predictors of psoriasis on response to systemic therapy
- Conditions
- L40Psoriasis
- Registration Number
- DRKS00017896
- Lead Sponsor
- AbbVie Deutschland GmbH & Co. KG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 381
Adult patients (= 18 years) with moderate to severe plaque psoriasis (defined by the European Consensus 2011 [5]) and present indication for conventional systemic psoriasis treatment (fumaric acid ester, MTX, cyclosporine, etc.) who are naive (untreated) to conventional psoriasis system therapy at the time of initiation of observation.
Patients who have already been treated with systemic psoriasis medications, i.e. are not naive to systemic psoriasis therapy and/or patients who are receiving PUVA therapy and/or patients who cannot or do not wish to sign the informed consent form
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Document the achievement of the 2011 European Consensus defined treatment goals after initial cessation of systemic treatment in the practical Routine<br><br>2. Assess whether or how the following basic parameters influence the achievement of treatment goals or disease course: <br>- severity of disease/extent of skin lesions<br>- quality of life (QoL)<br>- body weight, body mass index, waist and hip circumference, waist-hip ratio diagnosis of hypertension, type I/II diabetes mellitus, hyperlipidaemia<br>- history of disease with myocardial infarction stroke<br>- psoriatic arthritis, tobacco consumption<br>
- Secondary Outcome Measures
Name Time Method 1. Observe the achievement of treatment goals related to other parameters, including:<br>- Psoriasis-associated parameters (age, nail PsO, scalp PsO, age at onset of disease, disease duration concomitant medication (other diseases)<br>2. Period and number of change of regimen related to the above baseline parameters<br>